Results 21 to 30 of about 209,923 (292)

Carbohydrate antigen 19-9 elevation without evidence of malignant or pancreatobiliary diseases

Scientific Reports, 2020
Although carbohydrate antigen 19-9 (CA 19-9) may be elevated in benign diseases, elevated CA 19-9 may cause a fear of cancer and unnecessary follow-up studies. Research on how to approach systematically in this case is very limited.
Sunyoung Kim, B. Park, J. Seo, J. Choi, Jongwon Choi, C. Lee, J. Chung, Yongjung Park, Dong Wook Kim   +8 more
semanticscholar   +1 more source

Tumor Marker in Early Detection of Malignancies in Type 2 Diabetes: A Case Series Analysis

International Journal of Diabetes and Technology, 2023
The association between type 2 diabetes mellitus (T2DM) and malignancy has gained significant attention, with a heightened susceptibility to specific cancers.
Jothydev Kesavadev, Arun Shankar, Ashwin David Ashok, P. G. Balagopal, Gopika Krishnan, Anjana Basanth   +5 more
doaj   +1 more source

Diagnostic and Prognostic Value of CEA and CA19-9 in Colorectal Cancer

Diseases, 2021
Colorectal cancer (CRC) is the third most common cancer worldwide. A diagnosis at early stages with enhanced screening methods is vital as metastases and recurrences increase mortality.
Leilani Lakemeyer, Silvia Sander, Mathias Wittau, Doris Henne-Bruns, Marko Kornmann, Johannes Lemke   +5 more
doaj   +1 more source

Meta-analysis of the diagnostic performance of serum carbohydrate antigen 19-9 for the detection of gallbladder cancer

International Journal of Biological Markers, 2022
Introduction Carbohydrate antigen 19-9 (CA19-9) is a well-studied tumor marker, yet its diagnostic value for gallbladder cancer remains unclear. The present meta-analysis was conducted to validate the role of serum CA19-9 for the detection of gallbladder
Xiaolei Zhou
semanticscholar   +1 more source

CA 19-9 in Ovarian Immature Teratoma- A Potential Tumour Marker or A Masquerade? [PDF]

Journal of Clinical and Diagnostic Research, 2022
Carbohydrate antigen 19-9, also known as Cancer Antigen (CA 19-9) is a tumour marker found elevated in certain ovarian tumours. Although, reports of its association with mature teratoma are considerable, little is mentioned about its association with ...
Julie H John, R Sanghamita, Ajay Halder, Sramana Mukhopadhyay, Shweta Patel   +4 more
doaj   +1 more source

Using Tumor Marker Gene Variants to Improve the Diagnostic Accuracy of DUPAN-2 and Carbohydrate Antigen 19-9 for Pancreatic Cancer. [PDF]

J Clin Oncol
PURPOSE Circulating carbohydrate antigen 19-9 (CA19-9) levels reflect FUT3 and FUT2 fucosyltransferase activity. Measuring the related glycan, DUPAN-2, can be useful in individuals unable to synthesize CA19-9.
Ando Y, Dbouk M, Yoshida T, Saba H, Abou Diwan E, Yoshida K, Dbouk A, Blackford AL, Lin MT, Lennon AM, Burkhart RA, He J, Sokoll L, Eshleman JR, Canto MI, Goggins M.   +15 more
europepmc   +2 more sources

Construction of a Label-Free Electrochemical Immunosensor Based on Zn-Co-S/Graphene Nanocomposites for Carbohydrate Antigen 19-9 Detection

Nanomaterials, 2021
Nanocomposites of the binary transition metal sulfide Zn-Co-S/graphene (Zn-Co-S@G) were synthesized through a one-step hydrothermal method. They may be useful in the construction of an electrochemical immunosensor for carbohydrate antigen 19-9 (CA19-9 ...
Chia-Wei Su, Jia-Hao Tian, Jin-Jia Ye, Han-Wei Chang, Y. Tsai   +4 more
semanticscholar   +1 more source

Proposed carbohydrate antigen 19-9 (CA19-9) cut-off values for the detection of pancreatic cancer in patients with poorly controlled diabetes: a real-world study

Endocrine Journal, 2023
CA19-9 is a tumor marker for pancreatic cancer (PC), and the nondiabetic cut-off level is 37 U/mL. CA19-9 levels are said to rise in patients with tumors like PC and intraductal papillary mucinous neoplasm (IPMN). CA19-9 levels have also been shown to be
Taku Yamada, Taichi Minami, Masayo Yamada, Yasuo Terauchi   +3 more
doaj   +1 more source

Prognostic and therapeutic significance of carbohydrate antigen 19-9 as tumor marker in patients with pancreatic cancer [PDF]

, 2006
In pancreatic cancer ( PC) accurate determination of treatment response by imaging often remains difficult. Various efforts have been undertaken to investigate new factors which may serve as more appropriate surrogate parameters of treatment efficacy ...
Anderson JS, Bekaii-Saab TS, Brambs HJ, Burris HA, Ebrahimi B, Glenn J, Gogas H, Goggins M, Heinemann V, Heinemann V, Heinemann V, Ishii H, Jamieson NB, Jiang XT, Katz A, Ko AH, Koprowski H, Louvet C, Lundin J, Maisey NR, Montgomery RC, Moore MJ, Ni XG, Okusaka T, Petra Stieber, Philip PA, Ralf Wilkowski, Saad ED, Safi F, Safi F, Sakar B, Sawaki A, Sperti C, Stathopoulos GP, Stefan Boeck, Stefan Holdenrieder, Steinberg W, Tanaka N, Tempero MA, Tian F, van Custem E, Vimalachandran D, Volker Heinemann, Wilkowski R, Wilkowski R, Wilkowski R, Willet CG, Wolff RA, Ziske C   +48 more
core   +1 more source

Assessing prognosis in metastatic pancreatic cancer by the serum tumor marker CA 19-9: Pretreatment levels or kinetics during chemotherapy? [PDF]

, 2007
Background: The carbohydrate antigen 19-9 (CA 19-9) is currently the most widely used serum tumor marker in pancreatic cancer (PC). CA 19-9 pretreatment levels as well as CA 19-9 kinetics during systemic chemotherapy can provide prognostic information ...
Boeck, Stefan, Heinemann, Volker, Holdenrieder, Stefan, Schulz, Christoph, Stieber, Petra, Weckbach, Sabine   +5 more
core   +1 more source